On Wednesday 4 August, the European Commission signed an advance purchase agreement that will guarantee the EU-27 access to the protein-based Covid-19 vaccine NVX-CoV2373 developed by the US company Novavax.
The agreement will allow Member States to purchase up to 100 million doses of the vaccine and then activate an option to purchase an additional 100 million doses by 2023 if they so wish.
However, they will have to wait for the green light from the European Medicines Agency (EMA) to...